CymaBay Therapeutics Inc (CBAY.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2015||Chairman of the Board|
|42||2017||President, Chief Executive Officer|
|62||Senior Vice President, Chief Scientific Officer|
|47||2017||Vice President - Finance, Principal Financial Officer, Principal Accounting Officer|
|44||2015||Vice President - Regulatory Affairs and Quality Assurance|
- BRIEF-CymaBay Therapeutics Q1 Loss Per Share $0.32
- BRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis
- BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis
- BRIEF-Cymabay Reports Q4 Loss Per Share $0.11
- BRIEF-Cymabay Announces Pricing Of Public Offering Of Common Stock